FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2778063410> ?p ?o ?g. }

• W2778063410 endingPage "234" @default.
• W2778063410 startingPage "227" @default.
• W2778063410 abstract "Abstract Objectives To evaluate whether the subperiosteal injection of simvastatin ( SIM ) with a novel in situ gel‐forming system, Sr HA /Alg (strontium hydroxyapatite/alginate), can stimulate vertical bone augmentation in a rat calvarial model. Material and methods The Sr HA /Alg solution was synthesized and combined with different doses of SIM (0.01, 0.02, 0.1, and 0.2 mg) to form the following groups: (1) Sr HA /Alg only, (2) Sr HA /Alg/0.01, (3) Sr HA /Alg/0.02, (4) Sr HA /Alg/0.1, and (5) Sr HA /Alg/0.2. The SIM release pattern was analyzed, and rat primary periosteum‐derived cell ( PDC ) responses were investigated. Twenty male Wistar rats were enrolled in the calvarial subperiosteal injection experiment with each animal receiving a 200‐μl single subperiosteal injection of Sr HA /Alg with different amounts of SIM (0, 0.01, 0.02, and 0.1 mg) incorporated ( n = 5). The 0.2 mg dose group was not tested in vivo due to the severe toxicity found in vitro. The new bone formation was assessed histologically and radiologically at 8 weeks. Results The slow release of SIM was confirmed, and PDC viability decreased in the Sr HA /Alg/0.2 group. Alkaline phosphatase positive areas and mineralization areas were significantly greater in the Sr HA /Alg/0.01 and Sr HA /Alg/0.02 groups ( p < .05). The mRNA expression level of Runx2 significantly increased in the Sr HA /Alg/ SIM ‐0.02 group by day 7 ( p < .05) and significantly higher levels of VEGF were found in the Sr HA /Alg/0.01 and Sr HA /Alg/0.02 groups at different time points ( p < .05). In vivo, no prominent clinical sign of inflammation was observed, and the most significant bone gain was shown in the Sr HA /Alg/0.02 group ( p < .05). The osteoclast formation within the newly formed bone area was reduced in the Sr HA /Alg/0.1 group ( p < .05). Conclusions When combined with Sr HA /Alg system, the 0.02 mg SIM seemed to be the optimal dose to stimulate subperiosteal bone formation without inducing inflammation. This combination may hold potential therapeutic benefits for clinical bone augmentation in a minimally invasive manner." @default.
• W2778063410 created "2018-01-05" @default.
• W2778063410 creator A5021448305 @default.
• W2778063410 creator A5025911774 @default.
• W2778063410 creator A5028753933 @default.
• W2778063410 creator A5032199054 @default.
• W2778063410 creator A5036812674 @default.
• W2778063410 creator A5073952077 @default.
• W2778063410 date "2017-12-18" @default.
• W2778063410 modified "2023-10-18" @default.
• W2778063410 title "Injectable simvastatin gel for minimally invasive periosteal distraction: In vitro and in vivo studies in rat" @default.
• W2778063410 cites W1976490120 @default.
• W2778063410 cites W1978312067 @default.
• W2778063410 cites W1991536891 @default.
• W2778063410 cites W1992540727 @default.
• W2778063410 cites W1993154983 @default.
• W2778063410 cites W1996446383 @default.
• W2778063410 cites W1998906452 @default.
• W2778063410 cites W2000961900 @default.
• W2778063410 cites W2002154287 @default.
• W2778063410 cites W2009709078 @default.
• W2778063410 cites W2013061235 @default.
• W2778063410 cites W2017300493 @default.
• W2778063410 cites W2020364703 @default.
• W2778063410 cites W2020683718 @default.
• W2778063410 cites W2034803983 @default.
• W2778063410 cites W2042853716 @default.
• W2778063410 cites W2044626967 @default.
• W2778063410 cites W2074664839 @default.
• W2778063410 cites W2092540218 @default.
• W2778063410 cites W2153268447 @default.
• W2778063410 cites W2462983999 @default.
• W2778063410 doi "https://doi.org/10.1111/clr.13105" @default.
• W2778063410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29250831" @default.
• W2778063410 hasPublicationYear "2017" @default.
• W2778063410 type Work @default.
• W2778063410 sameAs 2778063410 @default.
• W2778063410 citedByCount "10" @default.
• W2778063410 countsByYear W27780634102018 @default.
• W2778063410 countsByYear W27780634102019 @default.
• W2778063410 countsByYear W27780634102020 @default.
• W2778063410 countsByYear W27780634102021 @default.
• W2778063410 countsByYear W27780634102022 @default.
• W2778063410 countsByYear W27780634102023 @default.
• W2778063410 crossrefType "journal-article" @default.
• W2778063410 hasAuthorship W2778063410A5021448305 @default.
• W2778063410 hasAuthorship W2778063410A5025911774 @default.
• W2778063410 hasAuthorship W2778063410A5028753933 @default.
• W2778063410 hasAuthorship W2778063410A5032199054 @default.
• W2778063410 hasAuthorship W2778063410A5036812674 @default.
• W2778063410 hasAuthorship W2778063410A5073952077 @default.
• W2778063410 hasConcept C105702510 @default.
• W2778063410 hasConcept C111696902 @default.
• W2778063410 hasConcept C134018914 @default.
• W2778063410 hasConcept C150903083 @default.
• W2778063410 hasConcept C160160445 @default.
• W2778063410 hasConcept C16685009 @default.
• W2778063410 hasConcept C178790620 @default.
• W2778063410 hasConcept C181199279 @default.
• W2778063410 hasConcept C185592680 @default.
• W2778063410 hasConcept C202751555 @default.
• W2778063410 hasConcept C207001950 @default.
• W2778063410 hasConcept C2776329913 @default.
• W2778063410 hasConcept C2777674748 @default.
• W2778063410 hasConcept C2993291840 @default.
• W2778063410 hasConcept C537208039 @default.
• W2778063410 hasConcept C55493867 @default.
• W2778063410 hasConcept C71924100 @default.
• W2778063410 hasConcept C86803240 @default.
• W2778063410 hasConceptScore W2778063410C105702510 @default.
• W2778063410 hasConceptScore W2778063410C111696902 @default.
• W2778063410 hasConceptScore W2778063410C134018914 @default.
• W2778063410 hasConceptScore W2778063410C150903083 @default.
• W2778063410 hasConceptScore W2778063410C160160445 @default.
• W2778063410 hasConceptScore W2778063410C16685009 @default.
• W2778063410 hasConceptScore W2778063410C178790620 @default.
• W2778063410 hasConceptScore W2778063410C181199279 @default.
• W2778063410 hasConceptScore W2778063410C185592680 @default.
• W2778063410 hasConceptScore W2778063410C202751555 @default.
• W2778063410 hasConceptScore W2778063410C207001950 @default.
• W2778063410 hasConceptScore W2778063410C2776329913 @default.
• W2778063410 hasConceptScore W2778063410C2777674748 @default.
• W2778063410 hasConceptScore W2778063410C2993291840 @default.
• W2778063410 hasConceptScore W2778063410C537208039 @default.
• W2778063410 hasConceptScore W2778063410C55493867 @default.
• W2778063410 hasConceptScore W2778063410C71924100 @default.
• W2778063410 hasConceptScore W2778063410C86803240 @default.
• W2778063410 hasFunder F4320324559 @default.
• W2778063410 hasIssue "2" @default.
• W2778063410 hasLocation W27780634101 @default.
• W2778063410 hasLocation W27780634102 @default.
• W2778063410 hasOpenAccess W2778063410 @default.
• W2778063410 hasPrimaryLocation W27780634101 @default.
• W2778063410 hasRelatedWork W1964487184 @default.
• W2778063410 hasRelatedWork W1997868327 @default.
• W2778063410 hasRelatedWork W2011384323 @default.
• W2778063410 hasRelatedWork W2044626967 @default.
• W2778063410 hasRelatedWork W2074211126 @default.

• next